Exciting news: Our blood test can reliably diagnose high-grade brain tumors

We just published new liquid biopsy data on the utility of circulating tumor cells for diagnosing glial malignancies in the International Journal of Cancer.

The study shows that our innovative blood test trublood Glioma for glial malignancies based on the detection of circulating glial cells can be used in order to get an accurate diagnosis if intracranial masses are malignant or not. In comparison to a brain biopsy, the risks of such a test are significantly lower. Regardless of gender and age, multiple grades (II-IV) and subtypes such as gliomas, astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas can be detected. The study means that patients with high-grade gliomas could receive faster confirmation of their diagnosis through a simple blood test instead of a biopsy, allowing treatment to begin sooner.

These findings have been achieved in a collaboration with the Brain Tumour Research Centre of Excellence at Imperial College London, Imperial College Healthcare NHS Trust and the Datar team.

This is another milestone in the fight against brain tumours!

Please check out the whole publication here:

Profiling of circulating glial cells for accurate blood‐based diagnosis of glial malignancies – O’Neill – International Journal of Cancer – Wiley Online Library

Brain Tumour Reserach also mentioned the study in an article:

Blood test proven to diagnose high-grade brain tumours – Brain Tumour Research